The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 778K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

35 articles for V Tsui


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
58
Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.EBI
Genentech
29
Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).EBI
Constellation Pharmaceuticals
48
Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.EBI
Genentech
19
The Rational Design of Selective Benzoxazepin Inhibitors of thea-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).EBI
Genentech
39
Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors.EBI
Genentech
13
Inhibiting the deubiquitinating enzymes (DUBs).EBI
Genentech
55
Lead identification of novel and selective TYK2 inhibitors.EBI
Genentech
33
2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors.EBI
Genentech
3
Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.EBI
Genentech
18
Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.EBI
Genentech
25
Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase.EBI
Genentech
8
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).EBI
Genentech
33
Rational design of phosphoinositide 3-kinasea inhibitors that exhibit selectivity over the phosphoinositide 3-kinaseß isoform.EBI
Genentech
10
Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.EBI
Genentech
20
Structure-based design of thienobenzoxepin inhibitors of PI3-kinase.EBI
Genentech
22
Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.EBI
Genentech
12
Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.EBI
Genentech
35
Antagonists of inhibitor of apoptosis proteins based on thiazole amide isosteres.EBI
Genentech
16
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.EBI
Genentech
43
Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.EBI
Gilead Sciences Inc.
11
Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance.EBI
Genentech
35
CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leads.EBI
Genentech
5
GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1.EBI
Constellation, A Morphosys
5
Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains.EBI
Genentech
19
Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.EBI
Genentech
28
GNE-371, a Potent and Selective Chemical Probe for the Second Bromodomains of Human Transcription-Initiation-Factor TFIID Subunit 1 and Transcription-Initiation-Factor TFIID Subunit 1-like.EBI
Genentech
36
Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300.EBI
Wuxi Apptec
21
GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP).EBI
Genentech
21
GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2).EBI
Genentech
17
Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability.EBI
Genentech
32
Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.EBI
Genentech
27
Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques.EBI
Genentech
26
A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors.EBI
Genentech
292
Tricyclic compounds as anticancer agentsBDB
Bristol Myers Squibb
6
Pyridine compounds used as PI3 kinase inhibitorsBDB
Teligene